Cancer drug letrozole is at the centre of a controversy over its being promoted as a fertility enhancer. The Union government has issued notices in this regard to Mumbai-based Sun Pharmaceuticals and Uttar Pradesh-based Dabur India Limited. While the latter has removed Foliripe -- the brand name under which it sells letrozole -- from the market, fresh evidence has reportedly surfaced that the former was encouraging the clinical trials of the medicine for this purpose
